# Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

> **NCT02110264** · PHASE3 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 151 (actual)

## Conditions studied

- Opioid Use Disorders

## Interventions

- **DRUG:** XR-NTX
- **BEHAVIORAL:** XR-NTX+PN
- **BEHAVIORAL:** ETAU

## Key facts

- **NCT ID:** NCT02110264
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-12
- **Final completion:** 2019-05
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110264, "Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02110264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*